Last reviewed · How we verify

NCT04836325: TSMFS-FMS

Effect of Transcranial Static Magnetic Field Stimulation in Fibromyalgia Syndrome

Completed NA Last updated 8 June 2022
What this trial tests

NA trial testing transcranial static magnetic field stimulation (tSMS) in Fibromyalgia in 16 participants. Completed in 30 November 2021.

Timeline
19 April 2021
Primary endpoint
31 October 2021
30 November 2021

Quick facts

Lead sponsorUniversity of Seville
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment16
Start date19 April 2021
Primary completion31 October 2021
Estimated completion30 November 2021
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

University of Seville

Who can join

Adults 18 to 75, any sex, with Fibromyalgia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective is to know if the transcranial static magnetic field stimulation (tSMS) reduces the perception of pain in patients with fibromyalgia and its effect on health-related quality of life. In addition, it will seek to limit the parameters necessary to achieve efficiency with the technique.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Fibromyalgia

Currently open trials in the same condition.

Other University of Seville trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04836325.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing